Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
HR (95% CI) | p | HR (95 % CI) | p | ||
Age | < 63 years | 0.67 (0.35–1.29) | 0.231 | ||
≥ 63 years | |||||
Gender | Male | 0.62 (0.32–1.20) | 0.156 | ||
Female | |||||
ECOG PS | 0 | 0.66 (0.34–1.28) | 0.226 | ||
1–2 | |||||
Stage | IIIA | 0.89 (0.54–1.48) | 0.663 | ||
IIIB | |||||
IIIC | |||||
Histology | Adenocarcinoma | 0.84 (0.41–1.70) | 0.635 | ||
Squamous Cell | |||||
Smoking status | Never | 0.59 (0.33–1.07) | 0.084 | 1.72 (0.26–11.00) | 0.567 |
Ex-smokers | |||||
Smoking at diagnosis | |||||
Mutational status | No | 0.99 (0.87–1.12) | 0.881 | ||
KRAS | |||||
PD-L1 | < 1% | 1.03 (0.67–1.59) | 0.882 | ||
1%–49% | |||||
> 50% | |||||
Time to durvalumab | < 57 days | 0.63 (0.32–1.24) | 0.186 | ||
≥ 57 days | |||||
RT dose | < 60 Gy | 1.10 (0.43–2.84) | 0.838 | ||
≥ 60 Gy | |||||
No of ChT | Up to 3 | 2.06 (0.94–4.51) | 0.069 | 0.83 (0.23–2.99) | 0.783 |
4–5 | |||||
ChT | Sequential | 1.51 (0.79–2.85) | 0.209 | ||
Concurrent | |||||
Response after IT | CR | 0.066 (0.008–0.518) | 0.010 | 0.067 (0.008–0.535) | |
PR/SD | |||||
Durvalumab treatment time | < 10.8 months | 3.16 (1.62–6.17) | 0.001 | 1.18 (0.227–6.17 | 0.841 |
≥ 10.8 months |
N = 85 (%) | ||
---|---|---|
N of ChT | 1 | 3 (3.5%) |
2 | 13 (15.3%) | |
3 | 41 (48.2%) | |
4 | 27 (31.8%) | |
5 | 1 (1.2%) | |
ChT | Gem/cis | 79 (92.9%) |
Etop/cis | 52 (61.2%) | |
Pem/cis | 3 (3.5%) | |
ChT | Induction | 82 (96.5%) |
Sequential only | 31 (36.5%) | |
Concurrent | 54 (63.5%) | |
Concurrent only | 3 (3.5%) | |
RT dose (Gy) | Median (range) | 60 (5 –66) |
V20 (Gy) | Median (range) | 27.2 (7.0–35.6) |
MLD (Gy) | Median (range) | 15.7 (4.0–20.2) |
PTV (cm3) | Median (range) | 416.6 (172.3–1282.6) |
Evaluation after ChT-RT | CR | 10 (11.8%) |
PR | 70 (82.3%) | |
SD | 5 (5.9 %) | |
Time between RT-IT (days) | Median (range) | 57 (12–99) |
Treatment characteristics | N (%) | P | |
---|---|---|---|
Time between RT-IT | Median (days) | 57 (12–99) | 0.689 |
< 57 | |||
≥ 57 | |||
Treatment time of IT |
Median (months) | 10.8 (0.5–12.0) | |
< 10.8 | |||
≥ 10.8 | |||
Treatment with IT | Completed | 41 (48.2%) | 0.095 |
Early stopped due to AE | 25 (29.4%) | ||
Progression | 16 (18.8%) | ||
Other | 3 (3.6%) | ||
Response after IT** | CR | 29 (34.1%) | 0.213 |
PR | 11 (12.9%) | ||
SD | 15 (17.6%) | ||
PD | 10 (11.8%) | ||
Progression*** | Loco-regional | 21 (24.7%) | 0.217 |
Metastatic | 10 (11.7%) | ||
Metastatic and local | 5 (5.9%) | ||
Metastatic spread | CNS | 5 (5.9%) | 0.101 |
Other | 10 (11.7 %) |
Progression (N of patients) | Loco-regional only | Metastatic | p | |
---|---|---|---|---|
Gender | Male | 12 | 10 | 0.563 |
Female | 9 | 5 | ||
Stage | IIIA | 7 | 3 | 0.663 |
IIIB | 11 | 9 | ||
IIIC | 3 | 3 | ||
Histology | Adenocarcinoma | 2 | 9 | |
Squamous cell | 19 | 5 | ||
Other | 0 | 1 | ||
Mutation | KRAS | 0 | 7 | |
No mutation | 21 | 8 | ||
PD-L1 | < 1% | 3 | 4 | |
1%–49 % | 8 | 6 | 0.435 | |
50 % | 10 | 4 |
N = 85 | ||
---|---|---|
Gender | Female | 25 (29.4 %) |
Male | 60 (70.6 %) | |
Age | Median (range) | |
< 63 | 63 (36 – 73) | |
≥ 63 | ||
ECOG PS | 0 | 37 (43.5 %) |
1 | 46 (54.1 %) | |
2 | 2 (2.4 %) | |
Smoking history | Never | 2 (2.4 %) |
Ex-smokers | 35 (41.6 %) | |
Smoking at diagnosis | 47 (56.0 %) | |
Histology | Adenocarcinoma | 31 (36.5 %) |
Squamous Cell | 50 (58.8 %) | |
Other | 4 (4.7 %) | |
AJCC 8th Edition Stage | IIIA | 26 (30.6%) |
IIIB | 48 (56.5 %) | |
IIIC | 11 (12.9 %) | |
PD-L1 Expression | < 1% | 13 (15.3 %) |
1%-49% | 33 (38.8 %) | |
> 50% | 32 (37.7 %) | |
Unavailable | 7 (8.2 %) | |
Mutational status | No mutations | 65 (76.5 %) |
KRAS | 16 (18.8 %) | |
Unavailable | 4 (4.7 %) |